VX-770 Expanded Access Program
NCT01381289 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2012-02-09
Summary
The purpose of this expanded access program is to provide VX-770 prior to its commercial availability to people with cystic fibrosis (CF) who have at least one copy of the G551D-CFTR mutation and who are in critical medical need and who are not eligible for participation in other Vertex-sponsored studies.
Conditions
Interventions
- DRUG
-
VX-770
150 mg tablet, oral use, twice daily every 12 hours (q12h)
Sponsors & Collaborators
-
Vertex Pharmaceuticals Incorporated
lead INDUSTRY
Eligibility
- Min Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Rollover Study of VX-770 in Cystic Fibrosis Subjects
NCT01117012 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
NCT07283770 ·Status: RECRUITING ·Phase: PHASE1
-
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
NCT00865904 ·Status: COMPLETED ·Phase: PHASE2
-
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT03768089 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT02070744 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT03227471 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01262352 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149 ·Status: COMPLETED ·Phase: PHASE3
-
Study of VX-770 and Rifampin in Healthy Male Subjects
NCT01018368 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
NCT02971839 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT06861413 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
NCT04038710 ·Status: COMPLETED
-
Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis
NCT00073463 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
NCT03912233 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
NCT02730208 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
NCT02951182 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT00953706 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03447262 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT05033080 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
NCT00909532 ·Status: COMPLETED ·Phase: PHASE3
-
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
NCT03278314 ·Status: APPROVED_FOR_MARKETING
-
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
NCT00457821 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
NCT03029455 ·Status: COMPLETED ·Phase: PHASE1